Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.
- Published In:
- Journal of pharmaceutical policy and practice, 18(1), 2441220 (2025)
- Database ID:
- RPEP-10738
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10738APA
DiStefano, Michael J; Dardouri, Mouna; Moore, Gina D; Saseen, Joseph J; Nair, Kavita V. (2025). Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.. Journal of pharmaceutical policy and practice, 18(1), 2441220. https://doi.org/10.1080/20523211.2024.2441220
MLA
DiStefano, Michael J, et al. "Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.." Journal of pharmaceutical policy and practice, 2025. https://doi.org/10.1080/20523211.2024.2441220
RethinkPeptides
RethinkPeptides Research Database. "Compounded glucagon-like peptide-1 receptor agonists for wei..." RPEP-10738. Retrieved from https://rethinkpeptides.com/research/distefano-2025-compounded-glucagonlike-peptide1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.